CD28 and Huntington disease: Upon Pep3 administration at day 6 of anti-CD3/CD28 stimulation no significant difference was observed in percentages of CD4+ Teff activated PD1+ cells (S7d Fig) and CD4+ Teff activated PD1low cells (S7e Fig) for both HD and type 1 diabetes PBMC.